Amylyx's Drug Shows Promise for Post-Bariatric Hypoglycemia
By Editor • August 18, 2026 • 1 min read
Amylyx Pharmaceuticals announced a major breakthrough with its experimental drug, demonstrating a significant impact on patients suffering from post-bariatric hypoglycemia (PBH).
In a Phase 3 trial, participants using the drug saw a 55% decrease in serious low blood sugar incidents compared to those on a placebo, surpassing initial expectations of a 35% improvement.
Co-CEO Justin Klee expressed enthusiasm, highlighting the importance of reducing such medical emergencies for patients and their families.
Source: www.statnews.com
